Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, 2-regimen, Repeat-dose Study to Assess the Safety and Pharmacokinetics of Intravenous CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis
Conditions
Interventions
Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody
Locations
11
Australia
Holdsworth House Medical Practice
Darlinghurst, Australia
Fremantle Dermatology
Fremantle, Australia
The Royal Melbourne Hospital
Parkville, Australia
Westmead Hospital
Westmead, Australia
Bispebjerg Hospital
Copenhagen, Denmark
Gentofte Hospital
Hellerup, Denmark
Start Date
July 4, 2019
Primary Completion Date
October 4, 2022
Completion Date
October 4, 2022
Last Updated
May 26, 2023
NCT06993233
NCT06888193
NCT07316192
NCT06768671
NCT06517732
NCT07228390
Lead Sponsor
CSL Behring
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions